Usage of and Attitudes About Green Tea Extract and Epigallocathechin-3-gallate (EGCG) As a Therapy in Individuals with Down Syndrome

Overview

Journal Complement Ther Med

Publisher Elsevier

Specialty Rehabilitation Medicine

Date 2019 Jul 24

PMID 31331567

Citations 4

Authors

Rachel Long

Montana L Drawbaugh

Charlene M Davis

Charles R Goodlett

Jane R Williams

Randall J Roper

Affiliations

Soon will be listed here.

Abstract

Objective: Usage of and views concerning alternative therapies in the DS community are not well documented. Some positive effects of green tea extracts (GTE) containing Epigallocathechin-3-gallate (EGCG) have been reported in individuals with DS and DS mouse models, but minimal improvements or detrimental effects of pure EGCG treatment have been reported in DS mouse models. Given the uncertainty about the effectiveness of these supplements, the goal of this study was to determine the relative prevalence of and attitudes about GTE/EGCG treatments among DS caregivers.

Methods: An anonymous survey about attitudes and usage of GTE/EGCG in individuals with DS was completed by caregivers of these individuals.

Results: GTE/EGCG treatment was provided by 18% of responding caregivers who were mostly younger, highly educated, and utilized scientific sources and other parents to influence their decision to use GTE/EGCG. Individuals with DS who received GTE/EGCG were characterized as less severely disabled. Most caregivers who did not give GTE/EGCG reported concerns about potential side effects and lack of effectiveness. Few caregivers consulted with medical providers about GTE/EGCG usage.

Conclusions: These results demonstrate a need for communication between caregivers, medical providers, and scientists about potential benefits and risks for adverse effects of GTE, EGCG, and other nutritional supplements in individuals with DS.

Citing Articles

The Role of Oxidative Stress in Trisomy 21 Phenotype.

Buczynska A, Sidorkiewicz I, Kretowski A, Zbucka-Kretowska M Cell Mol Neurobiol. 2023; 43(8):3943-3963.

PMID: 37819608 PMC: 10661812. DOI: 10.1007/s10571-023-01417-6.

Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.

Jamal R, LaCombe J, Patel R, Blackwell M, Thomas J, Sloan K PLoS One. 2022; 17(2):e0264254.

PMID: 35196359 PMC: 8865638. DOI: 10.1371/journal.pone.0264254.

From the lab to the people: major challenges in the biological treatment of Down syndrome.

Rondal J AIMS Neurosci. 2021; 8(2):284-294.

PMID: 33709029 PMC: 7940110. DOI: 10.3934/Neuroscience.2021015.

Down syndrome: A curative prospect?.

Rondal J AIMS Neurosci. 2020; 7(2):168-193.

PMID: 32607419 PMC: 7321764. DOI: 10.3934/Neuroscience.2020012.

References

Bauer C, Ishak M, Johnson E, Beebe-Dimmer J, Cooney K . Prevalence and correlates of vitamin and supplement usage among men with a family history of prostate cancer. Integr Cancer Ther. 2011; 11(2):83-9. PMC: 3213317. DOI: 10.1177/1534735411413262. View

de la Torre R, de Sola S, Hernandez G, Farre M, Pujol J, Rodriguez J . Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016; 15(8):801-810. DOI: 10.1016/S1474-4422(16)30034-5. View

Pons-Espinal M, Martinez de Lagran M, Dierssen M . Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. Neurobiol Dis. 2013; 60:18-31. DOI: 10.1016/j.nbd.2013.08.008. View

Werba J, Misaka S, Giroli M, Shimomura K, Amato M, Simonelli N . Update of green tea interactions with cardiovascular drugs and putative mechanisms. J Food Drug Anal. 2018; 26(2S):S72-S77. PMC: 9326886. DOI: 10.1016/j.jfda.2018.01.008. View

Abeysekera I, Thomas J, Georgiadis T, Berman A, Hammond M, Dria K . Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model. Mol Nutr Food Res. 2016; 60(4):717-726. PMC: 4828301. DOI: 10.1002/mnfr.201500781. View

Stringer M, Abeysekera I, Dria K, Roper R, Goodlett C . Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model. Pharmacol Biochem Behav. 2015; 138:70-9. DOI: 10.1016/j.pbb.2015.09.002. View

Blazek J, Abeysekera I, Li J, Roper R . Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a. Hum Mol Genet. 2015; 24(20):5687-96. DOI: 10.1093/hmg/ddv284. View

Maeda-Yamamoto M, Nishimura M, Kitaichi N, Nesumi A, Monobe M, Nomura S . A Randomized, Placebo-Controlled Study on the Safety and Efficacy of Daily Ingestion of Green Tea ( L.) cv. "Yabukita" and "Sunrouge" on Eyestrain and Blood Pressure in Healthy Adults. Nutrients. 2018; 10(5). PMC: 5986449. DOI: 10.3390/nu10050569. View

Stringer M, Abeysekera I, Thomas J, LaCombe J, Stancombe K, Stewart R . Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes. Physiol Behav. 2017; 177:230-241. PMC: 5525541. DOI: 10.1016/j.physbeh.2017.05.003. View

10.

Parker S, Mai C, Canfield M, Rickard R, Wang Y, Meyer R . Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol. 2010; 88(12):1008-16. DOI: 10.1002/bdra.20735. View

11.

Guedj F, Sebrie C, Rivals I, Ledru A, Paly E, Bizot J . Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One. 2009; 4(2):e4606. PMC: 2645681. DOI: 10.1371/journal.pone.0004606. View

12.

Dostal A, Samavat H, Bedell S, Torkelson C, Wang R, Swenson K . The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial. Food Chem Toxicol. 2015; 83:26-35. PMC: 4540665. DOI: 10.1016/j.fct.2015.05.019. View

13.

Lewanda A, Gallegos M, Summar M . Patterns of Dietary Supplement Use in Children with Down Syndrome. J Pediatr. 2018; 201:100-105.e30. DOI: 10.1016/j.jpeds.2018.05.022. View

14.

Becker W, Soppa U, Tejedor F . DYRK1A: a potential drug target for multiple Down syndrome neuropathologies. CNS Neurol Disord Drug Targets. 2013; 13(1):26-33. DOI: 10.2174/18715273113126660186. View

15.

Garcia-Alvarez A, Mila-Villarroel R, Ribas-Barba L, Egan B, Badea M, Maggi F . Usage of Plant Food Supplements (PFS) for weight control in six European countries: results from the PlantLIBRA PFS Consumer Survey 2011-2012. BMC Complement Altern Med. 2016; 16:254. PMC: 4964311. DOI: 10.1186/s12906-016-1227-5. View

16.

Hu J, Webster D, Cao J, Shao A . The safety of green tea and green tea extract consumption in adults - Results of a systematic review. Regul Toxicol Pharmacol. 2018; 95:412-433. DOI: 10.1016/j.yrtph.2018.03.019. View

17.

Duchon A, Herault Y . DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome. Front Behav Neurosci. 2016; 10:104. PMC: 4891327. DOI: 10.3389/fnbeh.2016.00104. View

18.

Roizen N . Complementary and alternative therapies for Down syndrome. Ment Retard Dev Disabil Res Rev. 2005; 11(2):149-55. DOI: 10.1002/mrdd.20063. View

19.

Bain J, McLauchlan H, Elliott M, Cohen P . The specificities of protein kinase inhibitors: an update. Biochem J. 2003; 371(Pt 1):199-204. PMC: 1223271. DOI: 10.1042/BJ20021535. View

20.

Zhu J, Seo J, Wang S, Ashby K, Ballard R, Yu D . The Development of a Database for Herbal and Dietary Supplement Induced Liver Toxicity. Int J Mol Sci. 2018; 19(10). PMC: 6213387. DOI: 10.3390/ijms19102955. View